Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 17.99M | $39.0M | 9.99% | +1.20M | 2026-06-30 |
| Orbimed Advisors LLC | 15.22M | $33.0M | 8.45% | -- | 2026-06-30 |
| Montanova Capital, LLC | 14.10M | $30.0M | 7.83% | -206.2K | 2026-06-30 |
| BlackRock, Inc. | 11.28M | $24.0M | 6.26% | +1.78M | 2026-06-30 |
| State Street Corp | 9.95M | $21.0M | 5.53% | +3.26M | 2026-06-30 |
| Enavate Sciences GP, LLC | 7.79M | $17.0M | 4.32% | -- | 2026-06-30 |
| Vivo Capital, LLC | 7.76M | $16.0M | 4.31% | -1.79M | 2026-06-30 |
| Vanguard Capital Management LLC | 6.12M | $13.0M | 3.40% | +81.6K | 2026-06-30 |
| Palo Alto Investors LP | 5.83M | $12.0M | 3.24% | +4.32M | 2026-06-30 |
| Millennium Management LLC | 4.71M | $10.0M | 2.62% | +3.87M | 2026-06-30 |
